Rules-Based Medicine

The deal is expected to expand Myriad's product portfolio into new disease areas, including psychiatric disorders, infectious diseases, and inflammatory conditions.

Using its DiscoveryMAP protein biomarker discovery platform, the company identified a biomarker pattern useful in monitoring disease progression and predicting and monitoring the efficacy of a compound in Roche's CNS pipeline.

RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.

RBM will use its TruCulture system as part of the institute's project to "establish the parameters that characterize the immune system of healthy individuals."

Myriad has acquired Rules-Based Medicine, taken steps to establish a European presence, and bolstered its companion diagnostics capabilities in an attempt to squelch negative Wall Street perceptions that it's a one-product company.

With the deal, Myriad will acquire RBM's biomarker discovery platform as well as its pipeline of proprietary protein biomarker-based diagnostics, including two tests that a Myriad official said were "relatively close to commercial launch."

The acquisition is expected to help build Myriad's companion diagnostics franchise.

The new guidelines mark the second publication in recent months to suggest that protein biomarkers be integrated into current definitions of Alzheimer's disease, though the new proposal explicitly calls for protein biomarkers to be used only in research settings.

New Products


Rules-Based Medicine, Plexera

Called plasmadiscover41, the panel comprises 41 plasma proteins thought to be potential biomarkers for various cancers. The company is also working on a 50- to 60-protein panel for CSF biomarkers that it plans to introduce in the second quarter.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.